Synageva BioPharma Employee Directory

Synageva BioPharma corporate office is located in 150 Lincoln St, Laurel Springs, New Jersey, 08021, United States and has 11-50 employees.

Employees by Department

Departments

Number of employees

Engineering & Technical

1

Operations

1

Marketing

1

Key Employees of Synageva BioPharma

  • MC
    United States flag for contact location.
    Michael Chen

    Director, Process Development & Production

    PhonePhoneEmailEmail
  • TY
    United States flag for contact location.
    Tamai Yukari

    Senior Director, Marketing

    PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail

Synageva BioPharma Global Presence

globalPresence illustration
Asia1-10
North America1-10
Europe1-10

Index of contact profiles from Synageva BioPharma

Hundreds of professionals searching for Synageva BioPharma have connected with key decision-makers. Join them?
Contact Name
Contact Info
Job Title
HQ Location
12

Former Employees at Synageva BioPharma

Explore people who held key positions, contributed to Synageva BioPharma's success, and advanced their careers.

People from Similar Companies in the Manufacturing Industry Located in New Jersey, United States

Frequently Asked Questions Regarding Synageva BioPharma Employees

How many employees does Synageva BioPharma have?
Synageva BioPharma has 11-50 employees
Who are Synageva BioPharma key employees?
Some of Synageva BioPharma key employees are Michael Chen, Tamai Yukari
Where is Synageva BioPharma located?
Synageva BioPharma’s headquarters are located at 150 Lincoln St, Laurel Springs, New Jersey, 08021, United States
How do I contact Synageva BioPharma?
Synageva BioPharma Contact Info: Phone number: (609) 469-0350 Website: www.synageva.com
What does Synageva BioPharma do?

Synageva is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company's pipeline consists of protein therapeutic programs for rare diseases with unmet medical need which are currently at various stages of development. The company is planning for a gl... obal launch of Kanuma for the treatment of LAL Deficiency and is dosing patients in a Phase 1/2 trial with its second, first-mover program, SBC-103 for MPS IIIB. The company's third, first-mover program, SBC-105, is an enzyme replacement therapy in preclinical development for disorders of calcification. In addition to these first-mover programs, the pipeline also consists of opportunities that leverage the company's manufacturing platform and other capabilities to create potentially bio-superior treatments for patient populations where there is still unmet medical need. The company has recently produced enzymes targeting Hunter syndrome, Fabry disease and Pompe disease with expression levels and activity that support further preclinical development. Synageva routinely posts information that may be important to investors in the Investor Relations section of the company's website at www.synageva.com. Synageva encourages investors and potential investors to consult this website regularly for important information about the company. Medical information regarding Kanuma and LAL Deficiency is available by email at medinfo@synageva.com.Read More

Is Synageva BioPharma a public company?
Synageva BioPharma is private company therefore does not currently have an official ticker symbol
See more information about Synageva BioPharma Employees

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.